Foley attorneys Heidi A. Sorensen and Judith A. Waltz are speaking at the American Health Lawyers Association’s (AHLA) Life Sciences Law Institute, May 7 – 9, 2008 in Bethesda, Maryland.
Ms. Sorensen and Ms. Waltz will be speaking on May 8, 2008 from 10:45 a.m. – 12:15 p.m. with Vickie L. McCormick, Chief Compliance Officer at St. Jude Medical. Their session title is “Trends in Corporate Integrity: Investigations and Obligations.” Topics to be covered include:
- Recent enforcement trends including deferred prosecution agreements, FCA settlements, OIG CMPL cases, and issues under the Foreign Corrupt Practices Act
- Lessons learned from the OIG’s corporate integrity agreements, including understanding the OIG’s expectations and goals
- Issues to consider in implementing and making operational a voluntary compliance program for a life sciences company
- Top do’s and don’ts for companies contemplating an OIG CIA
For more information, please visit AHLA’s Web site.
People
Related Insights
December 4, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
December 4, 2025
Foley Viewpoints
Foley Event Key Takeaways- Ready for Anything: Preparing for IPOs, SPACs, and Unexpected Capital Market Shift
Foley & Lardner, Protiviti and SS&C Intralinks recently hosted an event in Foley’s Silicon Valley office at Palo Alto Center. Moderated by Foley partner Louis Lehot, the session titled "Ready for Anything: Preparing for IPOs, SPACs, and Unexpected Capital Market Shifts," brought together industry leaders: JD Fay (ex-CFO, Matterport, de-SPAC’d and then sold to CoStar Group), Dan Angus (Managing Director, Nasdaq), and Andrea Vardaro Thomas (Managing Director, Protiviti). Their combined experience provided a roadmap for companies facing the volatile and rapidly shifting capital markets of 2026.
December 4, 2025
Foley Viewpoints
FDA Guidance on Biosimilars Highlights Glycosylation Profiling and Increases the Strategic Value of Patents Covering Antibodies Defined by Glycosylation
FDA’s September 2025 guidance requires detailed characterization of posttranslational modifications (PTMs), particularly glycosylation,…